These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 25821319)

  • 41. Clinical epidemiology, treatment and prognostic factors of extensively drug-resistant Acinetobacter baumannii ventilator-associated pneumonia in critically ill patients.
    Tsioutis C; Kritsotakis EI; Karageorgos SA; Stratakou S; Psarologakis C; Kokkini S; Gikas A
    Int J Antimicrob Agents; 2016 Nov; 48(5):492-497. PubMed ID: 27542315
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand.
    Koomanachai P; Tiengrim S; Kiratisin P; Thamlikitkul V
    Int J Infect Dis; 2007 Sep; 11(5):402-6. PubMed ID: 17291803
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Early Intravenous Colistin Therapy as a Favorable Prognostic Factor for 28-day Mortality in Patients with CRAB Bacteremia: a Multicenter Propensity Score-Matching Analysis.
    Kim T; Park KH; Yu SN; Park SY; Park SY; Lee YM; Jeon MH; Choo EJ; Kim TH; Lee MS; Lee E
    J Korean Med Sci; 2019 Oct; 34(39):e256. PubMed ID: 31602826
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of vancomycin in addition with colistin and meropenem against colistin-sensitive multidrug resistant Acinetobacter baumannii causing severe infections in a Paediatric Intensive Care Unit.
    Ceccarelli G; Oliva A; d'Ettorre G; D'Abramo A; Caresta E; Barbara CS; Mascellino MT; Papoff P; Moretti C; Vullo V; Visca P; Venditti M
    BMC Infect Dis; 2015 Sep; 15():393. PubMed ID: 26424078
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multidrug Resistance Acinetobacter Bacteremia Secondary to Ventilator-Associated Pneumonia: Risk Factors and Outcome.
    Brotfain E; Borer A; Koyfman L; Saidel-Odes L; Frenkel A; Gruenbaum SE; Rosenzweig V; Zlotnik A; Klein M
    J Intensive Care Med; 2017 Oct; 32(9):528-534. PubMed ID: 26902255
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Colistin against colistin-only-susceptible Acinetobacter baumannii-related infections: Monotherapy or combination therapy?
    Simsek F; Gedik H; Yildirmak MT; Iris NE; Türkmen A; Ersoy A; Ersöz M; Gücüyener A
    Indian J Med Microbiol; 2012; 30(4):448-52. PubMed ID: 23183471
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and efficacy of colistin alone or in combination in adults with Acinetobacter baumannii infection: A systematic review and meta-analysis.
    Wang J; Niu H; Wang R; Cai Y
    Int J Antimicrob Agents; 2019 Apr; 53(4):383-400. PubMed ID: 30447379
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia.
    Betrosian AP; Frantzeskaki F; Xanthaki A; Douzinas EE
    J Infect; 2008 Jun; 56(6):432-6. PubMed ID: 18501431
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predictors of mortality in patients with extensively drug-resistant Acinetobacter baumannii pneumonia receiving colistin therapy.
    Choi IS; Lee YJ; Wi YM; Kwan BS; Jung KH; Hong WP; Kim JM
    Int J Antimicrob Agents; 2016 Aug; 48(2):175-80. PubMed ID: 27423416
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment outcomes of patients with non-bacteremic pneumonia caused by extensively drug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex isolates: Is there any benefit of adding tigecycline to aerosolized colistimethate sodium?
    Jean SS; Hsieh TC; Lee WS; Hsueh PR; Hsu CW; Lam C
    Medicine (Baltimore); 2018 Sep; 97(39):e12278. PubMed ID: 30278498
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii pneumonia: experience in a tertiary care hospital in northern Taiwan.
    Lin CC; Liu TC; Kuo CF; Liu CP; Lee CM
    J Microbiol Immunol Infect; 2010 Aug; 43(4):323-31. PubMed ID: 20688293
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Outcomes in patients infected with carbapenem-resistant Acinetobacter baumannii and treated with tigecycline alone or in combination therapy.
    Guner R; Hasanoglu I; Keske S; Kalem AK; Tasyaran MA
    Infection; 2011 Dec; 39(6):515-8. PubMed ID: 21789524
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant
    Niu T; Luo Q; Li Y; Zhou Y; Yu W; Xiao Y
    Antimicrob Resist Infect Control; 2019; 8():52. PubMed ID: 30886705
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Predictors of hospital mortality among septic ICU patients with Acinetobacter spp. bacteremia: a cohort study.
    Shorr AF; Zilberberg MD; Micek ST; Kollef MH
    BMC Infect Dis; 2014 Oct; 14():572. PubMed ID: 25358621
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Integrating rapid diagnostics and antimicrobial stewardship improves outcomes in patients with antibiotic-resistant Gram-negative bacteremia.
    Perez KK; Olsen RJ; Musick WL; Cernoch PL; Davis JR; Peterson LE; Musser JM
    J Infect; 2014 Sep; 69(3):216-25. PubMed ID: 24841135
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Acinetobacter baumannii infections in a surgical intensive care unit: predictors of multi-drug resistance.
    Katsaragakis S; Markogiannakis H; Toutouzas KG; Drimousis P; Larentzakis A; Theodoraki EM; Theodorou D
    World J Surg; 2008 Jun; 32(6):1194-202. PubMed ID: 18408967
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical outcomes of children with carbapenem-resistant Acinetobacter baumannii bacteremia.
    Vandepitte WP; Berge J; Andersson R
    J Med Assoc Thai; 2014 Nov; 97 Suppl 11():S129-39. PubMed ID: 25509707
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial.
    Dickstein Y; Lellouche J; Ben Dalak Amar M; Schwartz D; Nutman A; Daitch V; Yahav D; Leibovici L; Skiada A; Antoniadou A; Daikos GL; Andini R; Zampino R; Durante-Mangoni E; Mouton JW; Friberg LE; Dishon Benattar Y; Bitterman R; Neuberger A; Carmeli Y; Paul M;
    Clin Infect Dis; 2019 Aug; 69(5):769-776. PubMed ID: 30462182
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii.
    Garnacho-Montero J; Amaya-Villar R; Gutiérrez-Pizarraya A; Espejo-Gutiérrez de Tena E; Artero-González ML; Corcia-Palomo Y; Bautista-Paloma J
    Chemotherapy; 2013; 59(3):225-31. PubMed ID: 24356297
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of parenteral colistin for the treatment of multiresistant Gram-negative organisms in major burn patients in South Korea.
    Cho YS; Yim H; Yang HT; Hur J; Chun W; Kim JH; Lee BC; Seo DK; Park JM; Kim D
    Infection; 2012 Feb; 40(1):27-33. PubMed ID: 21898119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.